|
US20220267475A1
(en)
*
|
2019-06-25 |
2022-08-25 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-cd47/anti-tigit bispecific antibody, preparation method therefor and application thereof
|
|
CN114072426B
(zh)
*
|
2019-07-08 |
2024-01-26 |
南京金斯瑞生物科技有限公司 |
抗cd47/抗pd-1双特异抗体及其制备方法和应用
|
|
EP4001309A4
(en)
*
|
2019-07-16 |
2023-08-16 |
Nanjing GenScript Biotech Co., Ltd. |
ANTI-CD47/ANTI-CTLA-4 BISPECIFIC ANTIBODY, METHOD FOR PREPARATION AND USE
|
|
CN114761041A
(zh)
|
2019-07-16 |
2022-07-15 |
吉利德科学公司 |
Hiv疫苗及其制备和使用方法
|
|
WO2021013215A1
(zh)
*
|
2019-07-23 |
2021-01-28 |
南京金斯瑞生物科技有限公司 |
抗cd47/抗lag-3双特异抗体及其制备方法和应用
|
|
CN112969715B
(zh)
*
|
2019-08-21 |
2022-03-18 |
和铂医药(上海)有限责任公司 |
一种抗cd47抗原结合蛋白及其应用
|
|
CN112442123B
(zh)
*
|
2019-09-03 |
2022-08-23 |
中山康方生物医药有限公司 |
抗cd47的单克隆抗体及其用途
|
|
CN114555123B
(zh)
|
2019-10-18 |
2024-04-02 |
四十七公司 |
用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
|
|
KR20220091576A
(ko)
|
2019-10-31 |
2022-06-30 |
포티 세븐, 인코포레이티드 |
혈액암의 항-cd47 및 항-cd20 기반 치료
|
|
JP7369297B2
(ja)
|
2019-12-17 |
2023-10-25 |
ファイザー・インク |
Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
|
|
LT4081305T
(lt)
|
2019-12-24 |
2024-11-25 |
Carna Biosciences, Inc. |
Diacilglicerolio kinazę moduliuojantys junginiai
|
|
KR20260017503A
(ko)
|
2020-02-14 |
2026-02-05 |
길리애드 사이언시즈, 인코포레이티드 |
Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
|
|
CN112679611B
(zh)
*
|
2021-01-18 |
2022-06-10 |
倍而达药业（苏州）有限公司 |
人源化cd47抗体或其抗原结合片段及应用
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
KR20220163991A
(ko)
*
|
2020-04-02 |
2022-12-12 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
Cd47에 결합하는 항원-결합 폴리펩타이드 및 이의 용도
|
|
TWI869582B
(zh)
*
|
2020-04-10 |
2025-01-11 |
大陸商和記黃埔醫藥（上海）有限公司 |
抗ｃｄ４７抗體及其用途
|
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
|
WO2022010806A1
(en)
*
|
2020-07-06 |
2022-01-13 |
ALX Oncology Inc. |
Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
|
|
JP7789304B2
(ja)
*
|
2020-07-31 |
2025-12-22 |
バイオ－テラ ソリュ－ションズ，エルティーディー． |
Ｃｄ４７抗体及びその応用
|
|
EP4192501A1
(en)
*
|
2020-08-04 |
2023-06-14 |
Exelixis, Inc. |
Cd47 binding agents and uses thereof
|
|
EP4217397A4
(en)
*
|
2020-09-28 |
2025-01-08 |
Shanghai Henlius Biotech, Inc. |
ANTI-CD47 ANTIBODIES AND METHODS OF USE
|
|
KR102757518B1
(ko)
*
|
2020-12-07 |
2025-01-21 |
(주)이노베이션바이오 |
Cd47에 특이적인 항체 및 이의 용도
|
|
US12071481B2
(en)
*
|
2020-12-23 |
2024-08-27 |
D-10 Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
|
CN116635426A
(zh)
*
|
2021-01-08 |
2023-08-22 |
北京韩美药品有限公司 |
特异性结合cd47的抗体及其抗原结合片段
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
CN117881698A
(zh)
*
|
2021-06-30 |
2024-04-12 |
创新生物有限公司 |
对cd47具有特异性的人源化抗体及包含其的用于预防或治疗cd47相关疾病的药物组合物
|
|
WO2023006391A1
(en)
*
|
2021-07-30 |
2023-02-02 |
Ludwig-Maximilians-Universität München |
Anti-cd47 antibodies and use thereof
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
EP4452415B1
(en)
|
2021-12-22 |
2026-02-25 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
CA3253296A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CN117257935A
(zh)
*
|
2022-06-21 |
2023-12-22 |
广东菲鹏制药股份有限公司 |
一种含抗cd47抗体或其抗原结合片段的制剂及其制备方法和应用
|
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CN119677546A
(zh)
|
2022-07-12 |
2025-03-21 |
吉利德科学公司 |
Hiv免疫原性多肽和疫苗及其用途
|
|
CN115932271A
(zh)
*
|
2022-09-02 |
2023-04-07 |
东曜药业有限公司 |
一种cd47抗体的试剂组合物及其应用
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4601692A1
(en)
*
|
2022-10-14 |
2025-08-20 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies targeting cd47 and uses thereof
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN120584133A
(zh)
*
|
2022-12-29 |
2025-09-02 |
上海复宏汉霖生物技术股份有限公司 |
抗cd47抗体及使用方法
|
|
CN120882725A
(zh)
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|